Amanda Przespolewski, a Buffalo native, joined the Leukemia service in July 2017. She earned her medical degree from the Lake Erie College of Osteopathic Medicine in 2011. Dr. Przespolewski completed her residency training in Internal Medicine at the University at Buffalo in 2014. In addition, she pursued her fellowship training in Hematology and Oncology at University at Buffalo, which was completed this past June. Amanda’s translational research interests include further understanding the role of MDSCs in MRD+ AML, and developing novel immune-based therapeutic approaches for this disease. In her free time, she enjoys hiking, cycling and traveling.
[Poster] Przespolewski A, Portwood S, Den Haese J, Lewis D, Wang ES. “Targeting Innate and Adaptive Immune Responses for the Treatment of Acute Myeloid Leukemia.” Accepted for presentation at the ASH Meeting on Hematologic Malignancies 9/17/16, and the ASH Annual Meeting 12/4/2016.
Przespolewski A, Wang ES. "Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia." Expert Opinion on Investigational Therapies. 2016 Apr 21:1-10. [Epub ahead of print].
[Poster] Mehta R, Torka P, Patel P, Przespolewski A, Levine E. “A Survey of Outpatient Chemotherapy Dosing Practices among Obese Patients in a Tertiary Care Cancer Center: Identification of Barriers and Implementation of Full Weight-Based Dosing.” Abstract, NCCN Annual Conference 3/2016.
Przespolewski A, Przespolewski E, and Hernandez F. "Ibrutinib in the Management of B-cell Malignancies." Journal of Targeted Therapies (2015): n. pag. 22 May 2015. Web.
Herko A, Pophali P, Wallace P, Loud P, Khoury T, and Battiwalla M. “T-cell large granular lymphocytosis associated with malignant thymoma.” Leukemia Research 36.8 (2012):e 187-189.